Form 4 for CRL Charles River Laboratories
Accepted 2026-06-02 16:46:05 ET · period of report 2026-05-29 · accession 0001100682-26-000101 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 16:46 | 2026-05-29 | CRL | Coleman Glenn | EVP, CFO | A - Grant | $180.71 | +6,640 | 27.8K | +31% | +$1.20M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-29 | A | A | 6,640 | $180.71 | 27,752 | D | — | — | (F1) Unvested restricted stock units annually ratably vest on May 29, 2027; May 29, 2028; May 29, 2029; and May 29, 2030. |